Immunization with Adenoviral Vectors Carrying Recombinant IL-12 and E7 Enhanced the Antitumor Immunity against Human Papillomavirus 16-associated Tumor
0
조회
0
다운로드
0
인용
0
참고문헌
초록
Abstract
Purpose: Human papillomavirus (HPV) infection has a significant role in cervical carcinogenesis, and HPV oncoprotein E7 plays an important part in the formation and maintenance of cervical cancer. Interleukin-12 (IL-12) has been reported to induce a cellular immune response, and to suppress the tumor growth and the E7 production. Here we describe the use of adenoviral delivery of the HPV 16 E7 subunit (AdE7) along with adenoviral delivery of IL-12 (AdIL-12) in mice with HPV-associated tumors. Materials and Methods: Mice were injected with TC-1 cells to establish TC-1 tumor, and then they were immunized with AdIL-12 and/or AdE7 intratumorally. The anti tumor effects induced by AdIL-12 and/or E7 were evaluated by measuring the size of the tumor. E7-specific antibody and INF-gamma production in sera, and the T-helper cell proliferative responses were then measured. Cytotoxic T-lymphocyte (CTL) and T cell subset depletion studies were also performed. Results: Combined AdIL-12 and AdE7 infection at the tumor sites significantly enhanced the antitumor effects more than that of AdIL-12 or AdE7 single infection. This combined infection resulted in regression of the 9 mm sized tumors in 80% of animals as compare to the PBS group. E7-specific antibody and INF-gamma production in the sera, and the T-helper cell proliferative responses were significantly higher with coinfection of AdIL-12 and AdE7 than with AdIL-12 or AdE7 alone. CTL response induced by AdIL-12 and AdE7 in the coinjected group suggested that tumor suppression was mediated by mostly CD8 and only a little by the CD4 T cells. Conclusion: IL-12 and E7 application using adenovirus vector showed antitumor immunity effects against TC-1 tumor, and this system could be use in clinical applications for HPV-associated cancer.
참고문헌 (25)
- "Regulation of human lymphocyte proliferationby a heterodimeric cytokine", j immu(l), pp.874~12 82 (1991)
- "Coexpression of two distinct genes isrequired to generate secreted bioactive cytotoxic lymphocytematuration factor", 88, pp.4143~47 (1991)
- "Interleukin-12:a proinflammatory cytokinewith immunoregulatory functions", 146, pp.423~31 (1995)
- "Charged residues dominate a unique interlocking topographyin the heterodimeric cytokine interleukin-12", 19, pp.3530~41 (2000)
- "Inhibitingcytokines of the interleukin-12 family: recent advances andnovel challenges.", 56, pp.145~60 (2004)
- "-specific immuneresponses and inhibits the development of IL-4producing Th cells", pp.1199~12 12 204 (1993), Trinchieri G
- "T cell and NK cell- independent inhibitionof hepatic metastases by systemic administration of an IL-12-expressing recombinant adenovirus", 160, pp.5465~74 (1998)
- "Fibroblasts genetically engineered to secreteinterleukin-12 can suppress tumor growth and induce antitumorgrowth and induce anti-tumor immunity to a murine melanomain vivo", 54, pp.182~9 (1994)
- "Engineered herpes simplex virus expressing IL-12in the treatment of experimental murine brain tumors", 97, pp.2208~13 (2000)
- "Canarypox virus-mediated interleukin 12 genetransfer into murine mammary adenocarcinoma induces tumorsuppression and long-term antitumoral immunity", 9, pp.2481~92 (1998)
- "Construction of a recombinant adeno-associated virus(rAAV) vector expressing murine interleukin-12 (IL-12)", 7, pp.308~15 (2000)
- "Cytokine gene therapy of cancer using gene gun technology superior antitumor activity of interleukin-12", 8, pp.1303~11 (1997)
- "Recombinant adeno-associated virus expressing humanpapillomavirus type 16 E7 peptide DNA fused with heat shockprotein DNA as a potential vaccine for cervical cancer", 74, pp.2888~94 (2000)
- "A recombinant vaccinia virusencoding human papillomavirus types 16 and 18, E6 and E7proteins as immunotherapy for cervical cancer.", 347, pp.1523~27 (1996)
- "Construction and characterisationof a recombinant vaccinia virus expressing human papillomavirusproteins for immunotherapy of cervical cancer", 14, pp.1485~94 (1996)
- "A therapy modality using recombinant IL-12 adenovirusplus E7 protein in a human papillomavirus 16 E6", E7-associated cervical cancer animal model, 2003, pp.14, 1389~99
- "Both E7 and CpG-oligodeoxynucleotide are required forprotective immunity against challenge with human papillomavirus16 (E6", E7) immortalized tumor cells: involvement ofCD4+ and CD8+ T cells in protection, 2002, pp.62, 7234~40
- "Cell-specific growth inhibition of human cervical cancer cellby recombinant adenovirus p53 in vitro and in vivo", 35, pp.181~90 (2003)
- "Transgene expression in the rhesus cervixmediated by an adenovirus expressing beta-galactosidase", 174, pp.1094~101 (1996)
- "Treatment of established tumorswith a novel vaccine that enhances major histocompatibilityclass II presentation of tumor antigen", 56, pp.21~6 (1996)
- "Induction of antitumor immunity by direct intratumoralinjection of a recombinant adenovirus vector expressinginterleukin-12", 6, pp.45~53 (1999)
- "purificationand immunological characterization of the transformingprotein E7", clin exp immu(l), pp.397~403 (1999), Expression
- "Cancer immunotherapy using a DNA vaccine encoding thetranslocation domain of a bacterial toxin linked to a tumorantigen", 61, pp.3698~703 (2001)
- "Adenoviral vectors targeted to CD40 enhance the efficacy ofdendritic cell-based vaccination against human papillomavirus16-induced tumor cells in a murine model", 60, pp.5456~63 (2000)
- "Cellular responsesto interferon-gamma. Annu Rev Immunol. 1997;15:749-95.to interferon-gamma.", 15, pp.749~95 (1997)